LLY Stock Price Today (June 2026) — Eli Lilly and Company Analysis & Key Metrics 2026-06-17
Eli Lilly and Company (LLY) is trading at $1112.00, down 0.94% today (as of June 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $1215.10 (9.3% upside).
- Volatility remains elevated (24.66% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (55.50% YoY) alongside significant competitive pressures.
LLY Stock Analysis: Key Metrics & Valuation (June 2026)
Concise, actionable data for investors
Eli Lilly and Company - Historical Price & Volume
Market Cap
Enterprise Value: $1.06T
P/E Ratio
Forward P/E: 25.83
Revenue Growth
Year over Year
Analyst Target
+9.3% upside potential
Key Investor Questions About LLY
What investors need to know before buying
Based on current market data, LLY presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 53.80)
- Fundamentals say: Caution warranted (high leverage concerns)
LLY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for LLY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $43.37B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, LLY stock traded between $623.78 and $1182.73—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.66% annualized volatility and β=0.64, the stock exhibits low sensitivity to market moves—making LLY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
J&J Has No Plans to Enter Obesity Drugs Market, CEO Says
Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.
J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030
Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.
Eli Lilly Stock's Trillion-Dollar Question
Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.
The Number That Could Test Johnson & Johnson Stock
The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.
Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock”
Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted worthy space players and reviewed several of this year’s IPOs. When a caller noted the high share price and ventured a guess that the company might split the stock, Cramer commented: I don’t know if they’re going to […]
Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug Pricing
Eli Lilly (NYSE:LLY) plans to reduce its previously announced €2.7b investment in Germany by half. The company links the cutback to European drug pricing reforms that it says could affect future R&D and manufacturing commitments. The decision highlights rising friction between large pharmaceutical companies and European governments over efforts to limit healthcare spending. Eli Lilly is a major global pharmaceutical company with a broad portfolio of branded drugs and a pipeline of new...
Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
Investing.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.
FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSS
Eli Lilly and Company (NYSE:LLY) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 9, the US FDA approved a new maintenance dosing regimen for Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), allowing adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every 8 weeks. […]
SpaceX's near $3 trillion rally comes with one big catch: Chart of the Day
SpaceX is already trading like one of America's biggest companies — its profits are not.
Frequently Asked Questions
Common investor questions about Eli Lilly and Company
Eli Lilly and Company (LLY) is currently trading at $1112.00. The RSI (14-day) is at 53.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $1215.10 implies 9.3% upside from current levels. Volatility is moderate at 24.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Eli Lilly and Company (LLY): The trailing P/E ratio is 39.50, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 25.83, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.52, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 31.85. Price-to-Sales is 13.72. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering LLY, the consensus price target is $1215.10. This represents a 9.3% upside from the current price of $1112.00. The range spans from a low target of $850.00 to a high target of $1500.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Eli Lilly and Company (LLY) pays a dividend with a current yield of approximately 62.00%. The annualized dividend rate is $6.23 per share. The payout ratio is 22.1%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-05-15T00:00:00.000Z.
Key risks for Eli Lilly and Company (LLY) investors include: 1. Elevated debt levels (D/E ratio of 139.01) which could pressure margins in a rising rate environment. 2. Elevated short interest (95.0% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Eli Lilly and Company's (LLY) current debt and financial health profile: Total debt stands at $43.37B. The debt-to-equity ratio is 139.01, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.50, indicating strong short-term liquidity. The quick ratio is 0.72. The company holds $5.28B in cash and equivalents. Free cash flow is positive at $9.16B, providing a cushion for debt servicing and shareholder returns.